Skip to main content

Table 3 Depression, anxiety, pain and quality of life scores throughout the study period

From: Trazodone for the treatment of fibromyalgia: an open-label, 12-week study

 

baseline

week 6

week 12

P (anova)

BDI-whole sample (mean ± s.d.)

28.0 ± 10.7

24.9 ± 12.3*

22.5 ± 10.7***

< 0.0001

ES

 

0.29

0.51

 

BDI > 18 (N = 41) (mean ± s.d.)

31 ± 9.2

26.9 ± 12.0*

23.3 ± 10.1***

< 0.0001

ES

 

0.45

0.84

 

HADS-depression (mean ± s.d.)

12.4 ± 4.9

11.6 ± 4.8

11.0 ± 5.0**

= 0.0142

ES

 

0.16

0.29

 

HADS depression > 7 (N = 43) (mean ± s.d.)

13.6 ± 3.8

12.5 ± 4.2

11.6 ± 4.5**

= 0.0054

ES

 

0.29

0.53

 

HADS anxiety (mean ± s.d.)

13.8 ± 4.2

13.1 ± 4.7

12.3 ± 4.9**

= 0.0041

ES

 

0.17

0.36

 

HADS anxiety >7 (N = 47) (mean ± s.d.)

14.5 ± 3.4

13.6 ± 4.3

12.7 ± 4.4**

= 0.0061

ES

 

0.26

0.53

 

BPI: mean pain severity (mean ± s.d.)

7.47 ± 1.6

7.00 ± 1.8*

6.95 ± 1.8*

= 0.0154

ES

 

0.29

0.33

 

BPI: pain interference with daily activities (mean ± s.d.)

8.42 ± 1.7

7.11 ± 2.2***

6.82 ± 2.6***

< 0.0001

ES

 

0.66

0.84

 

SF-36: PCS (mean ± s.d.)

27.3 ± 4.1

 

28.2 ± 5.2

N.S.

ES

  

-0.22

 

SF-36: MCS (mean ± s.d.)

28.0 ± 11.5

 

30.7 ± 12.5*

= 0.0383

ES

  

-0.23

 
  1. *: p < 0.05, **:p < 0.01, and ***: p < 0.001 in relation to baseline (Dunnett's post-test)
  2. ES: effect size; bold: moderate and large effect sizes